A phase 1, placebo-controlled, double-blind, dose-escalation study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of SM04690 injected in the target knee joint of moderately to severely symptomatic osteoarthritis subjects

Trial Profile

A phase 1, placebo-controlled, double-blind, dose-escalation study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of SM04690 injected in the target knee joint of moderately to severely symptomatic osteoarthritis subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Nov 2016

At a glance

  • Drugs SM 04690 (Primary)
  • Indications Osteoarthritis
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Samumed
  • Most Recent Events

    • 15 Nov 2016 Results published in the Samumed Media Release.
    • 01 Nov 2016 According to a Samumed media release, results from this trial will be presented at the 2016 American College of Rheumatology (ACR) Annual Meeting.
    • 04 Apr 2016 Results published in Samumed media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top